Treatment of tumor cell lines with IFN-γ induced differential upregulation of major histocompatibility complex (MHC) class I, which determines tumor cell sensitivity or resistance to natural killer (NK) cell-mediated lysis [6]. This evidence concerns the gene IFNG and neoplasm.